BofA analyst Tazeen Ahmad raised the firm’s price target on PTC Therapeutics (PTCT) to $84 from $68 and keeps a Buy rating on the shares. Sephience received a broad label for patients 1 month of age and older inclusive of all disease subtypes with no contraindications, notes the analyst, who calls the approval as “in-line with our expectations and a best-case scenario for the company” given no restrictions on disease subtype or treatment line. The firm models Q3 phenylketonuria sales of $2M, FY25 sales of $19.5M and peak sales of $1.3B in 2033.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics Receives Buy Rating Following FDA Approval of Sephience and Strategic Market Positioning
- PTC Therapeutics price target raised to $86 from $80 at Truist
- PTC Therapeutics: Buy Rating Driven by Sephience Approval and Market Strategy
- PTC Therapeutics price target raised to $78 from $74 at Wells Fargo
- Positive Outlook for PTC Therapeutics: Buy Rating Affirmed Following Sephience Approval and Strategic Launch